文献速递脑血管病

急性基底动脉闭塞血管内治疗的前瞻性登记研究

Assessment of Endovascular Treatment for Acute Basilar Artery Occlusion via a Nationwide Prospective Registry.
PubMed 文献 · JAMA Neurol · 2020-01-01

BASILAR研究为一项中国多中心前瞻性非随机队列研究,纳入829例急性基底动脉闭塞患者,比较标准药物治疗联合血管内治疗与单纯标准药物治疗。结果显示血管内治疗与90天功能结局改善、良好功能结局率更高及死亡率降低相关,但症状性颅内出血发生率增加。

要点

  • 急性基底动脉闭塞患者血管内治疗与90天功能结局改善独立相关。
  • 血管内治疗组90天良好功能结局率更高且死亡率更低。
  • 血管内治疗组症状性颅内出血发生率高于单纯药物治疗组。

核心结论

  • 急性基底动脉闭塞患者在估计闭塞时间24小时内接受血管内治疗与更好的功能结局和降低的死亡率相关。

研究设计与样本

  • BASILAR研究为前瞻性、非随机队列研究,纳入中国15个省份47家综合卒中中心连续收治的急性症状性、影像学确诊的基底动脉闭塞患者。
  • 共评估1254例患者,最终纳入829例,其中647例接受标准药物治疗联合血管内治疗,182例接受单纯标准药物治疗。
  • 纳入患者为估计闭塞时间24小时内的急性基底动脉闭塞患者,分为标准药物治疗联合血管内治疗组或单纯标准药物治疗组。

主要发现

  • 血管内治疗显著改善90天改良Rankin量表评分(校正共同优势比3.08,95%CI 2.09-4.55,P<.001)。
  • 血管内治疗与更高的90天改良Rankin量表评分≤3分率相关(校正优势比4.70,95%CI 2.53-8.75,P<.001)。
  • 血管内治疗与更低的90天死亡率相关(校正优势比2.93,95%CI 1.95-4.40,P<.001)。
  • 血管内治疗组症状性颅内出血发生率高于单纯药物治疗组(45/636例[7.1%] vs 1/182例[0.5%],P<.001)。

关键数值与推荐

  • 主要结局为90天改良Rankin量表评分(范围0-6分,评分越高残疾越重)的改善,采用序贯logistic回归移位分析校正预设预后因素后计算共同优势比。
  • 次要疗效结局为90天良好功能结局率,定义为改良Rankin量表评分≤3分(能独立行走)。
  • 安全结局包括症状性颅内出血和90天死亡率。

临床怎么用

  • 对于估计闭塞时间24小时内的急性基底动脉闭塞患者,血管内治疗可作为改善功能结局和降低死亡率的治疗选择。
  • 临床决策需权衡血管内治疗带来的功能获益与症状性颅内出血风险增加。

局限性

  • 本研究为非随机队列研究,可能存在选择偏倚和残余混杂。
  • 研究在中国进行,结果外推至其他人群需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Several randomized clinical trials have recently established the safety and efficacy of endovascular treatment (EVT) of acute ischemic stroke in the anterior circulation. However, it remains uncertain whether patients with acute basilar artery occlusion (BAO) benefit from EVT. OBJECTIVE: To evaluate the association between EVT and clinical outcomes of patients with acute BAO. DESIGN, SETTING, AND PARTICIPANTS: This nonrandomized cohort study, the EVT for Acute Basilar Artery Occlusion Study (BASILAR) study, was a nationwide prospective registry of consecutive patients presenting with an acute, symptomatic, radiologically confirmed BAO to 47 comprehensive stroke centers across 15 provinces in China between January 2014 and May 2019. Patients with acute BAO within 24 hours of estimated occlusion time were divided into groups receiving standard medical treatment plus EVT or standard medical treatment alone. MAIN OUTCOMES AND MEASURES: The primary outcome was the improvement in modified Rankin Scale scores (range, 0 to 6 points, with higher scores indicating greater disability) at 90 days across the 2 groups assessed as a common odds ratio using ordinal logistic regression shift analysis, adjusted for prespecified prognostic factors. The secondary efficacy outcome was the rate of favorable functional outcomes defined as modified Rankin Scale scores of 3 or less (indicating an ability to walk unassisted) at 90 days. Safety outcomes included symptomatic intracerebral hemorrhage and 90-day mortality. RESULTS: A total of 1254 patients were assessed, and 829 patients (of whom 612 were men [73.8%]; median [interquartile] age, 65 [57-74] years) were recruited into the study. Of these, 647 were treated with standard medical treatment plus EVT and 182 with standard medical treatment alone. Ninety-day functional outcomes were substantially improved by EVT (adjusted common odds ratio, 3.08 [95% CI, 2.09-4.55]; P < .001). Moreover, EVT was associated with a significantly higher rate of 90-day modified Rankin Scale scores of 3 or less (adjusted odds ratio, 4.70 [95% CI, 2.53-8.75]; P < .001) and a lower rate of 90-day mortality (adjusted odds ratio, 2.93 [95% CI, 1.95-4.40]; P < .001) despite an increase in symptomatic intracerebral hemorrhage (45 of 636 patients [7.1%] vs 1 of 182 patients [0.5%]; P < .001). CONCLUSIONS AND RELEVANCE: Among patients with acute BAO, EVT administered within 24 hours of estimated occlusion time is associated with better functional outcomes and reduced mortality.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Zi W, Qiu Z, Wu D, et al. Assessment of Endovascular Treatment for Acute Basilar Artery Occlusion via a Nationwide Prospective Registry. JAMA Neurol. 2020. PMID: 32080711. doi:10.1001/jamaneurol.2020.0156

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。